AnaptysBio (NASDAQ:ANAB) Trading Down 10.3% – Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB) shares were down 10.3% during trading on Friday . The stock traded as low as $60.18 and last traded at $58.2930. Approximately 200,639 shares changed hands during trading, a decline of 61% from the average daily volume of 512,750 shares. The stock had previously closed at $64.99.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Analyst price target raised ~21% to $79.82, signaling stronger analyst expectations for the stock’s upside. Read More.
• Positive Sentiment: Truist upgraded the stock, reinforcing the bullish analyst view alongside the higher price target and potentially supporting future buying interest. Read More.
• Positive Sentiment: Board authorized a $100 million stock repurchase program — a capital-return move that typically reduces float and signals management’s view that shares are undervalued. Read More.
• Positive Sentiment: Board approved the previously announced spin‑off of First Tracks Biotherapeutics; the new company is expected to begin trading as TRAX on Nasdaq on April 20, 2026 — a structural change that can unlock value if investors assign separate valuations. Read More.
• Positive Sentiment: First Tracks secured commitments of $145 million in a private placement, which should fund the spin‑out’s initial operations and reduce execution risk for the new company. Read More.
• Neutral Sentiment: The company provided a business update alongside the repurchase/spin‑off announcements; details strengthen the strategic narrative but will be judged on execution. Read More.
• Negative Sentiment: CEO Daniel Faga sold 17,679 shares (≈$1.09M) at an average $61.61 on March 27, reducing his stake ~3.44%; insider sales can trigger investor caution and may have contributed to intraday selling pressure. Read More. Read More.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Stifel Nicolaus lifted their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Truist Financial upgraded shares of AnaptysBio to a “hold” rating in a research report on Wednesday. UBS Group increased their price target on shares of AnaptysBio from $70.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Finally, Wedbush raised their price objective on shares of AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.44.

AnaptysBio Stock Performance

The business has a 50-day simple moving average of $55.30 and a two-hundred day simple moving average of $43.64. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -110.38 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The business had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. Research analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has approved a stock buyback program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in shares. This repurchase authorization permits the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In related news, CEO Daniel Faga sold 17,679 shares of the stock in a transaction dated Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the transaction, the chief executive officer directly owned 495,965 shares of the company’s stock, valued at $30,556,403.65. This represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the sale, the director owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. The trade was a 52.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 110,193 shares of company stock valued at $5,333,138. Insiders own 33.50% of the company’s stock.

Institutional Trading of AnaptysBio

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of AnaptysBio by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after buying an additional 67,048 shares in the last quarter. State Street Corp grew its holdings in AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after acquiring an additional 180,042 shares during the period. Assenagon Asset Management S.A. raised its position in AnaptysBio by 4,852.7% in the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after acquiring an additional 822,975 shares in the last quarter. 683 Capital Management LLC raised its position in AnaptysBio by 18.5% in the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 101,093 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in AnaptysBio in the fourth quarter valued at $21,559,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.